The genetically engineered vaccine against human chorionic gonadotropin enters Phase I/II clinical trials faces a problem, its possible resolution-Reference-Cited by-同舟云学术

The genetically engineered vaccine against human chorionic gonadotropin enters Phase I/II clinical trials faces a problem, its possible resolution

Published:2022-02-07 Issue: Volume:3 Page:2
ISSN:
Container-title:Journal of Reproductive Healthcare and Medicine
language:en
Short-container-title:JRHM

Author:

Talwar G. P.¹,Sehgal Rohini²,Shrivastava Mala³,Sharma R. S.⁴,Gupta Jagdish C.¹,Gupta Satish K.⁵,Buckshee Kamal⁶,Pal Priyanka¹,Nain Kirti¹,Kumar Sunesh²

Affiliation:

1. Talwar Research Foundation, All India Institute of Medical Sciences, New Delhi, India,

2. Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India,

3. Department of Obstetrics and Gynaecology, Sir Ganga Ram Hospital, New Delhi, India,

4. Department of Reproductive Biology, Maternal and Child Health, New Delhi, India,

5. Department of Basic Medical Sciences, Indian Council of Medical Research, New Delhi, India,

6. Department of Obstetrics and Gynecology, Fortis La Femme, Gurgaon, Haryana, India,

Abstract

Objectives: To determine the causes for formation of nodules in 5 out of 9 women immunized with the genetically engineered vaccine against hCG. Material and Methods: Studies were carried out in C57BL/6 strain of mice. Vaccine was given not only by intradermal but also by intramuscular route. Results: Nodules were formed in mice when vaccine was given by intradermal route but not by intramuscular route. No antibodies were measurable after 1 µg of the Protein version of the vaccine. However the vaccine given at 2 µg dose (equivalent to 388 µg human dose) induced good antibody response in every mouse. Conclusion: Vaccine may be given by intramuscular and not by intradermal route. The dose of the vaccine for women should be at least 300 µg of the Protein version of the vaccine after priming with the DNA version of the vaccine to induce antibody response.

Publisher

Scientific Scholar

Subject

Earth-Surface Processes,Soil Science,Agronomy and Crop Science,Soil Science,Aquatic Science,Soil Science,Microbiology,Soil Science,Geotechnical Engineering and Engineering Geology,Civil and Structural Engineering,General Energy,Soil Science,Ocean Engineering,Geotechnical Engineering and Engineering Geology,Water Science and Technology,Soil Science,Plant Science,Soil Science,Soil Science,Earth and Planetary Sciences (miscellaneous),Environmental Science (miscellaneous),Soil Science,General Engineering

Reference6 articles.

1. A vaccine that prevents pregnancy in women;Talwar;Proc Natl Acad Sci U S A,1994

2. Regain of fertility and normality of progeny born during below protective threshold antibody titres in women immunized with HSDhCG vaccine;Singh;Am J Reprod Immunol,1998

3. Development of a highly immunogenic recombinant candidate vaccine against human chorionic gonadotropin;Puruswani;Vaccine,2011

4. Polyphasic taxonomic analysis establishes Mycobacterium indicus pranii as a distinct species;Saini;PLoS One,2009

5. An immunotherapeutic vaccine for multibacillary leprosy;Talwar;Int Rev Immunol,1999